Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.79 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 14/20 | 1.00 |
| ▸ | DRD2 | P14416 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.79 |
| ▸ | THPO | P40225 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 4/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | MTOR | P42345 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7320300 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL7323497 | 0.99 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 | |
| Bromide SCHEMBL11496865 | 0.90 | DRD1 (0.82) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL11099766 | 0.89 | DRD1 (0.82) | DRD1DRD2KDM4EMAPTPMP22 | |
| Bromide SCHEMBL29634914 | 0.89 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 | |
| Bromide SCHEMBL12610614 | 0.89 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL34464664 | 0.88 | DRD1 (0.80) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL14495015 | 0.87 | DRD1 (0.79) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL30231809 | 0.87 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 | |
| SCHEMBL2970804 | 0.87 | DRD1 (1.00) | DRD1DRD2KDM4EMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | ADRA2A 40/4885SIGMAR1 63/4885DRD1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.